Back

Worsening renal function and hyperkalaemia in a real-life cohort treated with sacubitril/valsartan: findings from a prospective registry

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2018

About the speaker

Photo
Ms Laura Rodriguez

Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)

67 More presentations in this session

Presentation thumbnail
Combined therapy with ACEI/ARB, beta-blocker, statin, antithrombotic drug and cardiovascular mortality in comorbide patients with heart failure, coronary artery disease, arterial hypertension
Slides
Presentation thumbnail
Heart failure over 19 years: are we on the right way?
Presentation thumbnail
B-blockers and prognosis in cardiac amyloidosis
Doctor E. Repasos (Athens, GR)
Presentation thumbnail
Safety and efficacy of valsartan-sacubitril in a cohort of patients with symptomatic heart failure receiving small doses of ACE
Doctor A. Ntalianis (Athens, GR)
Presentation thumbnail
Barriers and motivations to physical activity in heart failure patients; is a specific approach needed for women?
Professor T. Jaarsma (Linkoping, SE)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources